Unique North American Male Reference Database
for Osteoporosis Diagnosis
Somerset, New Jersey, U.S.A. (May 15, 2002) -
Sunlight Omnisense™ 7000S is the only ultrasound bone sonometer
sold in North America with an approved male reference database.
This advantage has become increasingly important with the recent
approval of some bisphosphonates to treat osteoporosis in men.
Now more than ever, it is imperative that primary care physicians
have the tools to diagnose osteoporosis in men.
Osteoporosis is often perceived as a women's disease, but a growing number of men also suffer from the disease.
In 2002, some two million men in the United States have osteoporosis, and another 12 million are at risk.
The National Osteoporosis Foundation estimates that this number will rise to a total over 20 million men by 2020.
Perhaps more alarming is the fact that osteoporotic men have a higher rate of hip fracture - the most serious
consequence of osteoporosis - than women do. Up to one third of these male hip fracture patients will not survive
for more than a year following the fracture, and over half of the survivors will no longer be able to live
independently following the fracture.
Sunlight Omnisense™ 7000S is specifically designed to assess the bones of both male and female patients,
with two gender-based reference databases collected in North America. It uses a proprietary technology,
Omnipath™, which measures the Speed of Sound along the bone and eliminates the effect of soft tissue on measurement.
Moreover, measurement with Omnipath is not influenced by bone size, a parameter that differs significantly between
men and women. In contrast, measurements with technologies that assess bone mineral density are affected by the
size of the measured bone.
A recently published study about the Omnisense North American male reference database, which appeared in the Journal
of Clinical Densitometry in Spring 2002, included 588 healthy Caucasian males aged 20-90 years from six research centers
in North America. The study showed significant differences between bone strength values for men and women as they age.
Because of these significant differences in bone strength between the genders, it is important that physicians have
access to Z-scores - a comparison of a patient with an age- and gender-matched population - as a basis for diagnosis.
Increased demand for osteoporosis diagnosis for men in primary care has spurred the development of a male database for
the device. "Omnisense 7000S is the first and only peripheral ultrasound device with an approved male database as well
as measurement technology that is not influenced by bone size," explains Markus Maritz, president of Sunlight Medical, Inc.
"With these advantages, Omnisense is becoming the method of choice for the diagnosis of osteoporosis in men at primary care."
Sunlight Medical, the manufacturer of the device, develops, manufactures, and markets advanced,
high-technology medical devices for use at primary care facilities and hospitals. Currently,
Sunlight distributes PREMIER around the world for commercial use and in the United States for
research use only.
For more information on Sunlight Medical, Inc. or the Sunlight Omnisense™ 7000S bone sonometer,
contact David Helowicz, National Sales Manager, at (800) 750 6011, ext. 350, or visit Sunlight's
website at www.sunlightmedical.com.